Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bausch Health Companies Inc BHC


Primary Symbol: T.BHC

Healthcare
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with... see more

Recent & Breaking News (TSX:BHC)

New Scientific And Clinical Analyses Regarding Bausch + Lomb Surgical And Pharmaceutical Products To Be Presented During The Association For Research In Vision And Ophthalmology Meeting

Canada NewsWire April 26, 2019

IIROC Trade Resumption - BHC

Canada NewsWire April 25, 2019

FDA Approves Bausch Health's DUOBRII(TM) (Halobetasol Propionate And Tazarotene) Lotion 0.01%/0.045% For Plaque Psoriasis In Adults

Canada NewsWire April 25, 2019

IIROC Trading Halt - BHC

Canada NewsWire April 25, 2019

Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease

Canada NewsWire April 25, 2019

Bausch Health Companies Announces Participation In Upcoming Investor Conferences

Canada NewsWire April 24, 2019

Bausch + Lomb Reports More Than 9.2 Million Units Of Contact Lens Materials Diverted From Waste Stream Through ONE By ONE Recycling Program

Canada NewsWire April 22, 2019

Bausch Health Companies Inc. Will Release First-Quarter 2019 Financial Results On May 6

PR Newswire April 8, 2019

Bausch + Lomb Announces The U.S. Launch Of LOTEMAX® SM (Loteprednol Etabonate Ophthalmic Gel) 0.38% For The Treatment Of Postoperative Inflammation And Pain Following Ocular Surgery

PR Newswire April 2, 2019

Salix Enters Into License Agreement With The University Of California To Develop And Commercialize Novel Compound For The Treatment Of Non-alcoholic Fatty Liver Disease And Non-alcoholic Steatohepatitis

PR Newswire April 1, 2019

Ortho Dermatologics Launches 2019 Aspire Higher Scholarship Program For Students With Dermatologic Conditions

PR Newswire March 11, 2019

Bausch Health Announces Closing Of Senior Secured Notes And Add-On Unsecured Notes, As Well As Redemption Of Existing Senior Notes

PR Newswire March 8, 2019

Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offers And Consent Solicitation For Senior Notes

PR Newswire March 8, 2019

Bausch Health Completes Acquisition Of Certain Assets Of Synergy Pharmaceuticals Inc.

PR Newswire March 6, 2019

Ortho Dermatologics To Present New Analyses At The American Academy Of Dermatology Annual Meeting

PR Newswire February 28, 2019

Bausch Health to Acquire Certain Assets of Synergy Pharmaceuticals Inc.

PR Newswire February 26, 2019

Bausch + Lomb Announces FDA Approval Of LOTEMAX® SM (loteprednol Etabonate Ophthalmic Gel) 0.38% For The Treatment Of Postoperative Inflammation And Pain Following Ocular Surgery

PR Newswire February 25, 2019

Bausch Health Announces Upsize Of Cash Tender Offers And Consent Solicitation To $1,500,000,000 Aggregate Purchase Price

PR Newswire February 22, 2019

Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes And Add-On Unsecured Notes

PR Newswire February 22, 2019

Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes And Add-On Unsecured Notes

PR Newswire February 22, 2019